ACMT ToxIC Pediatric Marijuana and Opioid Registry (PEDMOP)
PEDMOP - Marijuana Sub Registry
With the legalization/decriminalization of marijuana in certain American states and the increased use of medical marijuana we have seen an associated increase in both hospital visits and cases of unintentional exposure by children reported to regional poison centers. There is relatively little in the medical literature describing the risk factors and presentation characteristics of these children. Effective preventive measures are needed as more states consider legalizing the drug and front-line providers must be alerted to the typical signs, symptoms and outcomes of children with marijuana intoxication.
PEDMOP - Opioid Sub Registry
Pediatric repercussions of the opioid epidemic are many including increased unintentional exposure in young children, increased neonatal abstinence syndrome, and increased intentional abuse by adolescents. While there are an increasing number of published reports in the literature, the details surrounding exposure, clinical presentation, management and outcomes in the pediatric age group have not been adequately studied in a prospective manner.
The purpose of ACMT’s Pediatric Marijuana and Opioid (PEDMOP) Sub Registry is to gather detailed prospective information regarding demographics, circumstances surrounding exposure, method of exposure, symptom profile, management and clinical course of children who present with opioid or marijuana intoxication; and, are cared for by medical toxicologists. The ultimate goal is to use the information gathered to develop appropriate guidance on the management of these exposures and to inform targeted prevention efforts.
All medical toxicologists who contribute cases to the registry may be listed as members of the ACMT ToxIC Pediatric Marijuana and Opioid (PEDMOP) Registry study group, which will be credited in all publications stemming from the registry. For reports on the entire registry, individually listed authors will include 1-2 investigators from the site contributing the most cases to the registry, and a single investigator from the next two sites with the highest case contribution. For case series on individual types of exposures, individually listed authors will include 1-2 investigators from the two sites contributing the most cases of that type to the registry, as well as a single investigator from the next two sites with the highest case contribution. All other contributors will be considered as such (PubMed searchable by name).
Principal Investigators Contact Information
Adrienne L. Davis, MD and Yaron Finkelstein, MD, FACMT
Hospital for Sick Children, Toronto, Ontario, Canada
email@example.com ; firstname.lastname@example.org
416-813-7654 x202384 (Adrienne); 416-813-5317 (Yaron)